Eagle-Tribune5d
MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End
Strong Safety Profile Validated Across Studies, Setting the Stage for Clinical Trials in Neuropathic Pain ...
Telefonica (0TDE) Receives a Hold from Barclays
In a report released today, Mathieu Robilliard from Barclays maintained a Hold rating on Telefonica (0TDE – Research Report). The company’s ...